Since Jan. 1, the following drugmakers announced or completed mergers, acquisitions, partnerships and general transactions.
Note: This is not an exhaustive list. Deals were reported by Becker’s Hospital Review, beginning with the most recent.
1. Danaher buys GE’s biopharmaceutical unit for $21.4B
Danaher Corp., a Fortune 500 science and technology conglomerate, will buy General Electric’s biotechnology business for $21.4 billion in cash.
2. Roche strikes $4.8B deal to acquire Spark Therapeutics
Drug giant Roche will buy gene therapy developer Spark Therapeutics for about $4.8 billion in cash.
3. Merck to acquire Immune Design for $300M
Drugmaker Merck will acquire oncology company Immune Design for $300 million in cash.
4. J&J to buy robotic surgery startup Auris Health for $3.4B
Johnson & Johnson will shell out $3.4 billion in cash to buy robotic surgery company Auris Health.
5. Takeda finalizes Shire takeover, now among top 10 drugmakers worldwide
Takeda finalized its $62 billion acquisition of Shire Jan. 8, catapulting the Japanese company into a new league of pharma giants.
6. Eli Lilly buys Loxo Oncology for $8B
Eli Lilly plans to acquire Loxo Oncology for $8 billion in cash to expand its portfolio of cancer medications.
7. Bristol-Myers to buy Celgene for $74B
Bristol-Myers Squibb plans to acquire cancer drugmaker Celgene for $74 billion in cash and stock — one of the largest deals in pharmaceutical history.
More articles on pharmacy:
5 recent pharma bankruptcies
Top 10 fatal or harmful prescribing errors
Civica Rx will start as middleman for drugmakers, hospitals, Bloomberg says
